Cost-effectiveness of prostate cancer screening: A simulation study based on ERSPC data

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Heijnsdijk, E A M ^a   De Carvalho, T M D ^a   Auvinen, A ^b   Zappa, M ^c   Nelen, V ^d   Kwiatkowski, M ^e   Villers, A ^f   Paez A ^g   Moss, S M ^h   Tammela, T L J ⁱ   Recker, F ^e   Denis, L ^d,j   Carlsson, S V ^i,l   Wever, E M ^a   Bangma, C H ^a   Schroder F H ^a   Roobol, M J ^a   Hugosson, J ^k   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Institute for Cancer Prevention   (Italy)

^d Provinciaal Instituut voor Hygiene   (Belgium)

^e Provinciaal Instituut voor Hygiëne ^*  (Switzerland)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^j Oncology Centre of Antwerp   (Belgium)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; AGE; BLOOD; COMPUTER SIMULATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; EUROPE; LABORATORY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

AGE FACTORS; AGED; BIOMARKERS, TUMOR; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EUROPE; FALSE POSITIVE REACTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 84928714134     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju366     Document Type: Article

References (42)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Prostatecancer mortality at 11 years of follow-up. N Engl J Med. 2012;366(11):981-990.
2. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101(6):374-83.
3. Heijnsdijk EA, der Kinderen A, Wever EM, et al. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009;101(11):1833-8.
4. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367(7):595-605.
5. Garg V, Gu NY, Borrego ME, et al. A literature review of costeffectiveness analyses of prostate-specific antigen test in prostate cancer screening. Expert Rev Pharmacoecon Outcomes Res 2013;13(3):327-42.
6. Martin AJ, Lord SJ, Verry HE, et al. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Med J Aust 2013;198(10):546-50.
7. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection because of prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-78.
8. Wever EM, Draisma G, Heijnsdijk EA, et al. How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med Decis Making 2011;31(4):550-8.
9. Wever EM, Hugosson J, Heijnsdijk EA, et al. To be screened or not to be screened? Modeling the consequences of PSA screening for the individual. Br J Cancer 2012;107(5):778-84.
10. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17):2095-101.
11. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100(16):1144-54.
12. OECD Health Data, Organisation for Economic Co-operation and Development, Pars, France. (Accessed June 5, 2013 at http://www.oecd.org/els/health-systems/OECDHealth-Data2012FrequentlyRequestedData-Updated-October.xls#'Public).
13. Postma R, Schröder FH, van Leenders GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007;52(1):89-97.
14. Otto SJ, van der Cruijsen IW, Liem MK, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105(3):394-9.
15. The guidelines manual January 2009. National Institute for Health and Clinical Excellence, 2009. (Accessed April 28, 2009, at http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp.).
16. The Cost-Effectiveness Analysis Registry, Center for the Evaluation of Value and Risk in Health. Boston, ICRHPS, Tufts Medical Center. (Accessed June 5, 2013 at http://www.cearegistry.org).
17. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11(8):725-732.
18. Wever EM, Heijnsdijk EA, Draisma G, et al. Treatment of localregional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. Br J Cancer 2013;108(10):1971-7.
19. Bermudez-Tamayo C, Martin Martin JJ, Gonzalez Mdel P, et al. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml. Urol Int 2007;79(4):336-44.
20. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative PSA-based prostate cancer screening strategies. Ann Intern Med 2012; in press.
21. Perez-Niddam K, Thoral F, Charvet-Protat S. Economic evaluation of a prostate cancer screening program in France: a decision model. Crit Rev Oncol Hematol 1999;32(2):167-73.
22. Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284(11):1399-405.
23. Ross KS, Guess HA, Carter HB. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology 2005;66(5):1038-42.
24. Sennfält K, Sandblom G, Carlsson P, et al. Costs and effects of prostate cancer screening in Sweden - a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 2004;38(4):291-8.
25. Barry MJ, Fleming C, Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program. Urology 1995;46(4):445-61.
26. Benoit RM, Gronberg H, Naslund MJ. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 2001;4(3):138-45.
27. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med 1997;126(6):468-79.
28. Howard DH. Life expectancy and the value of early detection. J Health Econ 2005;24(5):891-906.
29. Kobayashi T, Goto R, Ito K, et al. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective. Eur J Surg Oncol 2007;33(6):783-9.
30. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer. A decision analytic view. JAMA 1994;272(10):773-80.
31. Zhang J, Denton BT, Balasubramanian H, et al. Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making 2012;32(2):337-49.
32. Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol 2011;185(3):828-32.
33. Grenabo Bergdahl A, Holmberg E, Moss S, et al. Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial. Eur Urol 2013;64(5):703-9.
34. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, epub ahead of press.
35. Johansson E, Steineck G, Holmberg L, et al. Long-term qualityof-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12(9):891-9.
36. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250-61.
37. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 2009;339:b4817.
38. Booth N, Rissanen P, Tammela TL, et al. Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer. Eur Urol 2014;65(1):39-47.
39. Sox HC. Quality of life and guidelines for PSA screening. N Engl J Med 2012;367(7):669-71.
40. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol 2013;13:04308-5.
41. Moyer VA. Screening for Prostate Cancer: U. S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;157(2):120-134.
42. Gulati R, Tsodikov A, Wever EM, et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012;23(6):827-35.